Zaleplon

扎来普隆

Report date: 2022/04/18 09:47:31
NME

Base Information

Drug NameZaleplon
Drug Alias NameStaccato-zaleplon扎莱普隆札来普隆zaleplonumZaleplon AP +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor modulators
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsDepressive DisorderSleep Initiation and Maintenance DisordersSleep Wake Disorders +[4] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaSleep Initiation and Maintenance Disorders
Original Approved Country/TerritoryEU
Original Approved Date1999/03/11
Country/TerritoryUnited StatesIsraelEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesAurora Optoelectronics Co Ltd
Inactive CompaniesAlexza Pharmaceuticals IncPfizer IncMeda Ab +[6] 
Active IndicationsSleep Initiation and Maintenance Disorders
Inactive IndicationsDepressive DisorderSleep Wake DisordersAcquired Immunodeficiency Syndrome

Other Information

ATC CodeN05CF03
Related LinksWikipediaDrugBankKEGG